CBO Remains Skeptical Of Rx Cost Savings In Medicare Estimates

The Congressional Budget Office's baseline numbers for a prescription drug benefit should account for cost-savings achieved by preventative medicines, House Energy & Commerce/Health Subcommittee Chairman Bilirakis (R-Fla.) suggested during a May 16 hearing.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet